Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

316 questions · 321 findings · 136 reviews

No studies found 52 · 16.2%GRADE not reported 21 · 6.5%Very low 115 · 35.8%Low 92 · 28.7%Moderate 33 · 10.3%High 8 · 2.5%

Evening vs morning dosing regimen

Withdrawals due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater

It is very uncertain whether evening changes withdrawals from treatment due to adverse events compared with morning dosing regimen (very low certainty).

1 finding from 1 review

Corticosteroids vs placebo

Withdrawals due to adverse events · inactive EoE patients

Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).

1 finding from 1 review

Biologics vs placebo

Withdrawals due to adverse events · active EoE patients

Biologics showed no clear difference in withdrawals due to adverse events 12 to 44 weeks compared with placebo (low certainty).

1 finding from 1 review

Topical clonidine (TC) vs placebo

Withdrawals due to adverse events · adults with painful diabetic neuropathy

Topical clonidine (TC) showed no clear difference in withdrawals due to adverse events during longest compared with placebo (low certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Withdrawals due to adverse events not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

WIthdrawals due to Adverse Events ‐ not reported · patients with shoulder pain

The review found no eligible studies for this question.

1 finding from 1 review

Infliximab vs placebo

Withdrawals due to adverse events · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).

1 finding from 1 review

Corticosteroids vs placebo

Withdrawals due to adverse events · active EoE patients

Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).

1 finding from 1 review

Adjunctive Coriolus versicolor vs no adjunctive treatment

Withdrawals due to adverse events · adults (aged 18+) with colorectal cancer

It is very uncertain whether adjunctive Coriolus versicolor changes withdrawal from treatment due to adverse events ‐ compared with no adjunctive treatment (very low certainty).

1 finding from 1 review

Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).

1 finding from 1 review

Sulfasalazine vs placebo

Withdrawals due to adverse events · Patients with ankylosing spondylitis

Sulfasalazine probably leads to higher total number of withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Methotrexate vs placebo

Withdrawals due to adverse events · children and young people with JIA

Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).

1 finding from 1 review

Intervention not reported

Withdrawal from intervention due to adverse events · people with severe frostbite injuries
1 finding from 1 review

Intervention not reported

Withdrawal from intervention due to adverse events · people with severe frostbite injuries
1 finding from 1 review

Intervention not reported

Withdrawal from intervention due to adverse events · people with severe frostbite injuries
1 finding from 1 review

Summary of findings table ‐ Topical capsaicin vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral gabapentin vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review